[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-471956-105":59,"doc-detail-471956-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","special-510k-device-modification-oir-decision-summary","SPECIAL 510(k) - Device Modification OIR Decision Summary","","SPECIAL 510(k) Device Modification OIR Decision Summary prepared for K173839 explains acceptable information for a 510(k) submission covering modifications to the applicant’s own class II/class I devices. It confirms the indication and intended use have not changed and describes labeling elements and required user/service documentation. The submission details two technical changes, including replacing amplification/labeling reagents with the GeneChip™ 3' IVT Pico Kit and updating chip processing software to Genechip™ System 3000 Dx v.2. It further includes comparison to the predicate device and risk analysis with verification and validation studies demonstrating concordant results under specified confidence intervals.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/special-510k-device-modification-oir-decision-summary/471956/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/special-510k-device-modification-oir-decision-summary/471956.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What modification is covered in this 510(k) submission for K173839?","Question",{"text":112,"@type":113},"The submission covers modifications to the applicant’s own devices requiring 510(k), including replacing the amplification/target labeling reagent kit and updating the chip processing software to a supported version.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Did the submission state that the indication or intended use changed?",{"text":117,"@type":113},"No. It states that the indication/intended use described in the labeling has not changed, and the labeling includes instructions for use, package labeling, and any available promotional materials.",{"name":119,"@type":110,"acceptedAnswer":120},"What validation evidence is provided for the reagent and software changes?",{"text":121,"@type":113},"A validation study using 142 specimens compared results between the RampUp RNA Amplification Kit™ and the GeneChip™ 3' IVT Pico Kit, showing 90.8% concordance with a stated confidence interval. A separate software validation study using 20 FFPE tumor specimens compared Genechip™ System 3000 Dxv.2 to Genechip™ System 3000 Dx, showing 100% agreement with a stated confidence interval.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},471956,1793043038,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":81,"preview_urls":144},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","SPECIAL 510(k): Device Modification OIR Decision Summary  \nTo: THE FILE RE: K173839  \nThis 510(k) submission contains information/data on modifications made to the applicant’s own class II or class I devices requiring 510(k) . The following items are present and acceptable:  \n1. The name and 510(k) number of the applicant’s previously cleared device:  \nK120489: Pathwork Tissue of Origin Test Kit-FFPE  \n2. Applicant’s statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials.  \n3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user’s and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.  \nThe following two changes were made: 1) the GeneChip™ 3' IVT Pico Kit is used for amplification and target labeling instead of the RampUp RNA Amplification Kit™ reagents; and 2) the Chip processing software was updated to the Genechip™ System 3000 Dx v.2 from the Genechip™ System 3000 Dx, which is no longer supported by the manufacturer. The principles of the target preparation process have not changed.  \n4. Comparison Information (similarities and differences) to applicant’s legally marketed predicate device including, intended use, equipment, reagents and limitations, are summarized in the table below:  \n\n| Feature | K120489 (Predicate) | K173839 |\n| --- | --- | --- |\n| Device Name | Pathwork Tissue of Origin Test Kit-FFPE | Cancer Genetics Tissue of Origin Test Kit-FFPE |\n| Intended use | The Pathwork Tissue of Origin Test is an in vitro diagnostic intended to measure the degree of similarity between the RNA expression patterns ina patient's formalin-fixed, paraffin-embedded (FFPE) tumor and the RNA expression patterns ina database of fifteen tumor types (poorly differentiated, undifferentiated, and metastatic cases) that were diagnosed according to then current clinical and pathological practice. This test should be evaluated by a qualified physician in the context of the patient's clinical history and other diagnostic test results.\u003Cbr>Limitations:The Pathwork® Tissue of Origin Test isnot intended to establish the origin of tumors (e.g. cancer of unknown primary) that cannot be diagnosed according to current clinical and pathological practice. It is not intended to subclassify or modify the classification of tumors that can be diagnosed by current clinical and pathological practice, nor to predict disease course or survival or treatment efficacy, nor to distinguish primary from metastatic tumor. Tumor types not in the Pathwork® Tissue of Origin Test database may have RNA expression patterns that are similar to patterns in the database. Therefore, results cannot be used to distinguish tumor types in the database from tumor types not in the database. | Same |\n| Microarray | Pathchip® | Same |\n| Equipment | Hybridization oven | Same |\n|  | Scanner | Same |\n|  | Genechip™ System 3000 Dx | Genechip™ System 3000 Dx v.2 |\n| RNA isolation | Extraction Reagents | Same |\n| Amplification\u003Cbr>Reagents | RampUp RNA Amplification Kit™ | GeneChip™ 3' IVT Pico Kit |\n| Purification of biotinylated cDNA | Ethanol precipitation | GeneChip™ 3' IVT Pico Kit |\n| Internal Processing Quality Control | Percent Positive\u003Cbr>Overall Signal\u003Cbr>Regional Discontinuity | Same |\n| Analysis | Algorithm as described in K092967 | Same |\n\n5. A Design Control Activities Summary which includes:  \na) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis  \nb) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied  ","cbCainxvO7r1uYN2","https://ap.wps.com/l/cbCainxvO7r1uYN2","pdf",193145,"English","# Overview\n## Predicate device identification and unchanged intended use\n## Device modification description\n## Comparison to predicate device\n## Design control, risk analysis, and validation results","[{\"question\":\"What modification is covered in this 510(k) submission for K173839?\",\"answer\":\"The submission covers modifications to the applicant’s own devices requiring 510(k), including replacing the amplification/target labeling reagent kit and updating the chip processing software to a supported version.\"},{\"question\":\"Did the submission state that the indication or intended use changed?\",\"answer\":\"No. It states that the indication/intended use described in the labeling has not changed, and the labeling includes instructions for use, package labeling, and any available promotional materials.\"},{\"question\":\"What validation evidence is provided for the reagent and software changes?\",\"answer\":\"A validation study using 142 specimens compared results between the RampUp RNA Amplification Kit™ and the GeneChip™ 3' IVT Pico Kit, showing 90.8% concordance with a stated confidence interval. A separate software validation study using 20 FFPE tumor specimens compared Genechip™ System 3000 Dxv.2 to Genechip™ System 3000 Dx, showing 100% agreement with a stated confidence interval.\"}]","SPECIAL 510(k) - Device Modification OIR Decision Summary | PDF",1790779976,[145,149,153],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/5d5d7df8d876b3c2192778a5ba1a7d87.webp",983,1272,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/8403c04d3a5bd9ee7b0d016defcd18f3.webp",982,1270,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/8224ee374c0bdb66949a9918039864ea.webp",981,1269]